Novo Nordisk began distributing its first GLP-1 tablet intended for the treatment of obesity in Estados Unidos, marking a significant evolution in the therapeutic options available. Esta innovation, which hits the market as an oral alternative to weekly injections, promises to expand access to effective treatments for weight control, which is a public health challenge for millions of people. The arrival of this medicine signals a new chapter in obesity management, prioritizing convenience and accessibility for patients.
Prices for the new drug range from $149 to $299 per month for cash payments, positioning it as a more cost-effective option compared to injectable GLP-1 treatments. Estes The latter, while effective, often have a sticker cost that can reach $1,000 per month without insurance coverage, creating significant financial barriers for many.
The initial availability of the tablet already covers a wide distribution network, facilitating access for consumers:
- More than 70,000 pharmacies nationwide, including major retailers like CVS and Costco.
- Select telehealth partners such as Ro, LifeMD, and Weight Watchers offering purchasing flexibility.
Details about accessibility and costs
Novo Nordisk’s pricing strategy for its oral medication actively seeks to overcome affordability barriers that have historically limited adoption of obesity treatments, especially those with restricted insurance coverage. By offering competitive price ranges for cash payments, the company seeks to make the treatment viable for a wider portion of the population living with the condition. Esta approach aims to not only boost long-term treatment adherence, but also contribute to better public health outcomes by enabling a greater number of patients to effectively manage their body weight with a more convenient option.
Launch and market availability
The official launch of the tablet, marketed as Wegovy oral, occurred just weeks after its approval by the Food and Drug Administration (FDA) of the Estados Unidos. The regulatory agency granted the go-ahead for the treatment in December, allowing Novo Nordisk to move quickly with the drug’s introduction.
The initial dose of 1.5 milligrams of the tablet is now available to the public. Novo Nordisk also reported that higher doses of the drug will be gradually released to patients throughout the week, as communicated by sources such as GoodRx and the NovoCare pharmacy, ensuring a continuous and staggered supply.
Pricing and coverage options
For patients who choose to pay directly for treatment, the initial dose of the oral medication has a monthly cost of US$149, seeking to attract a wide audience with a more affordable alternative.
Additionally, the 4-milligram dose of the tablet will be offered for US$149 per month until April 15th. Após this date, the price for this dosage will be US$ 199 per month. The highest doses, 9 and 25 milligrams, will be available for US$299 per month, consolidating a varied pricing structure.
Patients with insurance coverage for the drug can benefit from a significantly reduced cost, with the ability to pay as little as US$25 per month for treatment, which represents a major financial relief and expands access for those with comprehensive health plans.
Exclusive agreement and market future
A strategic collaboration between Novo Nordisk and Donald Trump Administration will allow patients to purchase an initial dose of the tablet for $149 through the direct-to-consumer website TrumpRx, with its launch scheduled for January. Este agreement reinforces the effort to diversify access channels to medicine.
This initiative highlights the search for innovative distribution routes, offering yet another alternative for individuals seeking effective treatments for weight control and who can benefit from subsidized prices through strategic partnerships.
Novo Nordisk emphasized that the availability of the oral tablet “opens new possibilities” for the more than 100 million Americans facing obesity, underscoring the potential impact of this innovation on the public health landscape.
The GLP-1 drug market, in which Novo Nordisk and Eli Lilly stand out as key players, is projected to reach an estimated value of US$100 billion by the 2030s, with oral treatments expected to capture a considerable share of this segment.
Competition and therapeutic advances
Although the Novo Nordisk and Eli Lilly injections are sold with a list price close to US$1,000 per month, both companies now offer more affordable cash payment options, with prices ranging between US$299 and US$499 per month, depending on the dosage. The introduction of the oral format intensifies competition in this dynamic market and substantially expands the therapeutic choices available to patients seeking weight control.
Novo Nordisk’s launch of the daily oral medication gives the company a head start in the rapidly growing GLP-1 market. The FDA approved the treatment in December, while a decision on a competing drug to Eli Lilly is expected later this year, shaping the competitive landscape and future treatment options for obesity.
Dual approval and clinical efficacy
In addition to its primary approval for the treatment of obesity, the Novo Nordisk tablet also received FDA approval for reducing the risk of serious cardiovascular events. Essa indication includes the prevention of death, heart attack or stroke in adults diagnosed with obesity and established cardiovascular disease, significantly expanding its therapeutic value and the group of patients who may benefit.
Mechanism of action and study results
The oral medication shares the same active ingredient, semaglutide, which is the active substance found in the popular injectable Wegovy. Sua action consists of mimicking the intestinal hormone GLP-1, which plays a crucial role in suppressing appetite and regulating satiety, thus aiding weight loss.
Phase three studies, involving more than 300 adults with obesity, demonstrated the effectiveness of the highest dose of oral semaglutide. Participants experienced an average loss of up to 16.6% of their body weight over 64 weeks of treatment, confirming the clinical benefits of the drug.
